{"id":8641,"date":"2025-11-25T23:04:18","date_gmt":"2025-11-25T23:04:18","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/11\/25\/fda-approves-otsuka-kidney-disease-therapy\/"},"modified":"2025-11-25T23:04:18","modified_gmt":"2025-11-25T23:04:18","slug":"fda-approves-otsuka-kidney-disease-therapy","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/11\/25\/fda-approves-otsuka-kidney-disease-therapy\/","title":{"rendered":"STAT+: FDA approves Otsuka kidney disease therapy"},"content":{"rendered":"<p>    STAT+: FDA approves Otsuka kidney disease therapy<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>The Food and Drug Administration on Tuesday approved the first drug from an emerging class of medicines for patients with chronic, autoimmune kidney disease, according to a <a href=\"https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2025\">notice<\/a> on the agency\u2019s website.<\/p>\n<p>The new drug, called Voyxact, is made by Otsuka, the Japanese pharmaceutical company. U.S. regulators cleared it to treat IgA nephropathy, or IgAN, a disease caused by the build-up of immune antibodies in the kidneys. The condition leads to progressive loss of kidney function and potentially organ failure requiring dialysis.<\/p>\n<p>\u201cWe are excited to make a new treatment option available to nephrologists and their patients,\u201d said John Kraus, Otsuka\u2019s chief medical officer, in an interview with STAT prior to the posting of approval decision.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/11\/25\/fda-approves-otsuka-kidney-disease-therapy\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/11\/25\/fda-approves-otsuka-kidney-disease-therapy\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: FDA approves Otsuka kidney disease therapy The Food and Drug Administration on Tuesday approved the first drug from an emerging class of medicines for patients with chronic, autoimmune kidney disease, according to a notice on the agency\u2019s website. The new drug, called Voyxact, is made by Otsuka, the Japanese pharmaceutical company. U.S. regulators cleared [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2362,2176,2155,2152],"tags":[2150],"class_list":["post-8641","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-chronic-disease","category-pharma","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8641"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8641"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8641\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}